Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
English Version English Version
  MedUni Wien  trenner  Intranet  trenner  MedUni Wien - Shop  trenner  Universitätsbibliothek  trenner  Universitätsklinikum AKH Wien  trenner
 
Krebsforschung.png
 
 
 
Hauptnavigation
  • Home
  • Mission Statement
    • Chronik
    • 50 Jahre Institut für Krebsforschung
    • Imagevideo: Institut für Krebsforschung
  • Forschung
    • Forschungsschwerpunkte
    • Forschungsgruppen
    • Wissenschaftliche Services - Core Facilities
  • Lehre
    • Vorlesungen und Seminare des Institutes
    • Universitätslehrgang Toxikologie für Postgraduierte
    • PhD Program Inflammation and Immunity
    • PhD Program IPPTO Translational Oncology
    • PhD Programm Malignant Diseases
    • PhD Programm Clinical and Experimental Oncology
  • Kontakt
    • Kontakt
    • Lageplan
 
Forschung / Forschungsschwerpunkte / Angewandte und experimentelle Onkologie / Petra Heffeter
 
Subnavigation
  • Forschungsschwerpunkte
    • Zelluläre und molekulare Tumorbiologie
    • Angewandte und experimentelle Onkologie
      • Walter Berger
      • Martin Filipits
      • Petra Heffeter
        • Research Projects
        • Group Members
      • Michael Grusch
      • Klaus Holzmann
      • Hedwig Sutterlüty
    • Sicherheit chemischer Substanzen und Krebsprävention
    • Progression und Metastasierung von Tumoren
  • Forschungsgruppen
  • Wissenschaftliche Services - Core Facilities


Inhaltsbereich

 

Petra Heffeter, Univ.-Prof. Mag. Dr. MAS
Gruppenleiterin
E-Mail: Petra.Heffeter [at] meduniwien [dot] ac [dot] at
Phone: +43 (0)1 40160 - 57594
Fax: +43 (0)1 40160 - 957555

Research Focus

Chemotherapy and therapy with small targeted molecules are two major strategies for therapy of human cancer at the disseminated stage. During the last decades, thousands of compounds have been developed and consequently have improved therapy effectiveness. However, even when using new targeted therapeutics, such therapy is often limited by strong side effects, resistance development and insufficient tumor accumulation.

The research of this group is focused on the development of several new strategies to overcome these limitations:

1.    Improvement of anticancer activity by smart drug combinations;

2.    Development of new targeting strategies to increase drug delivery to the tumor tissue (in cooperation with the Institute of Inorganic Chemistry, Vienna within “Forschungsplattform Translational Cancer Therapy Research“;

3.    Investigation on the mechanisms underlying the sensitivity/resistance of cancer cells against new anticancer drugs to define the patient collective which will profit most from chemotherapy.

Financial support: Austrian Science Fund (FWF), AWS Prize 2015, Initiative Krebsforschung, Herzfelder'sche Familienstiftung, Fellinger Krebsforschung, Fonds der Stadt Wien für innovative interdisziplinäre Krebsforschung

Group Members

Videos

Selected Publications

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.
Mayr J, Heffeter P (corresponding author), Groza D, Galvez L, Koellensperger G, Roller A, Alte B, Haider M, Berger W, Kowol CR*, Keppler BK.;
Chem Sci Issue 3, 2017 (IF 9.1)

Impact of Stepwise NH2-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention.
Kowol CR, Miklos W, Pfaff S, Hager S, Kallus S, Pelivan K, Kubanik M, Enyedy ÉA, Berger W, Heffeter P (correspondig author), Keppler BK.;
J Med Chem. 2016 Jul 28;59(14):6739-52. doi: 10.1021/acs.jmedchem.6b00342. (IF5.6)

Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.
Kryeziu K, Pirker C, Englinger B, van Schoonhoven S, Spitzwieser M, Mohr T, Körner W, Weinmüllner R, Tav K, Grillari J, Cichna-Markl M, Berger W, Heffeter P.;
Oncotarget. 2016 May 10;7(19):27379-93. doi: 10.18632/oncotarget.8415. (IF 5.0)

Triapine-mediated ABCB1 induction via PKC induces widespread therapy unresponsiveness but is not underlying acquired triapine resistance.
Miklos W, Pelivan K, Kowol CR, Pirker C, Dornetshuber-Fleiss R, Spitzwieser M, Englinger B, van Schoonhoven S, Cichna-Markl M, Koellensperger G, Keppler BK, Berger W, Heffeter P.;
Cancer Lett. 2015 May 28;361(1):112-20. doi: 10.1016/j.canlet.2015.02.049

Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation.
Karnthaler-Benbakka C, Groza D, Kryeziu K, Pichler V, Roller A, Berger W, Heffeter P, Kowol CR.;
Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12930-12935. doi: 10.1002/anie.201403936.

 

 

All Publications:

PubmedDatabase

 
Drucken
 
 
© MedUni Wien | Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt